Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type I is a fibrillar protein forming the primary structural scaffold of the extracellular matrix in the dermis, providing tensile strength, elasticity, and resistance to stretching. It is synthesized as procollagen in fibroblasts, undergoes post-translational modification (hydroxylation, glycosylation), is secreted, and then assembled extracellularly into mature collagen fibrils. Type I collagen’s abundance and organized fibril formation are essential for youthful skin and wound healing, whereas its degradation or misregulation is associated with aging, scarring, and fibrotic diseases. Drugs can target collagen synthesis (e.g., retinoids enhance, corticosteroids suppress) or degradation (e.g., collagenases for contractures). Biomarkers of collagen turnover are used to monitor diseases like fibrosis and the efficacy of anti-aging/repair interventions.
Enzymatic degradation (collagenases), stimulation of collagen synthesis (retinoids, vitamin C)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type I (Collagen I).